[EQ] Costs of HIV Prevention Among Out-of-Treatment Drug-Using Women

Costs of HIV Prevention Among Out-of-Treatment Drug-Using Women:

Results of a Randomized Controlled Trial

Jennifer Prah Ruger,a; Arbi Ben Abdallah, b; Linda Cottler, b

A Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT

B Department of Psychiatry, Washington University School of Medicine, St. Louis, MO
Association of Schools of Public Health

Public Health Reports / 2010 Supplement 1 / Volume 125

Available online at: http://publichealthreports.org/archives/issueopen.cfm?articleID=2353

 

Objectives.
We developed a micro-costing methodology to estimate the real resource costs consumed by delivery of the National Institute on Drug Abuse

(NIDA) Cooperative Agreement Standard Intervention (SI) for human immunodeficiency virus (HIV) prevention, plus two enhanced modules, in a three-arm

randomized controlled trial (RCT) among drug-using women. To our knowledge, this is the first micro-costing study of the SI and enhanced modules and

the first of its kind targeting drug-using women.

Methods.
We conducted a micro-costing study alongside a three-arm RCT to estimate costs of (1) the modified NIDA SI; (2) the SI and a well woman exam

(SI1WWE); and (3) the SI, WWE, and four educational sessions (SI1WWE14ES) to prevent HIV and sexually transmitted diseases in at-risk, drug-using women

in St. Louis, Missouri.

Results.
The cost of the SI that all 501 participants received was approximately $227 per person. The additional costs for the WWE and 4ES were approximately

$145 and $942 per person, respectively. Total program costs for the SI (n5501) were $113,869; additional costs for the SI1WWE (n5342) were $49,403 and for the SI1WWE14ES (n5170) were $160,189. The main cost component for the SI (64% of total costs) was testing costs, whereas building and facilities costs were the main cost component for the SI1WWE14ES (75% of total costs).

Conclusions.
This study provides accurate estimates of the real costs for standard and enhanced HIV interventions for policy makers seeking to implement targeted HIV-prevention programs with scarce resources.

 

 *      *     *
This message from the Pan American Health Organization, PAHO/WHO, is part of an effort to disseminate
information Related to: Equity; Health inequality; Socioeconomic inequality in health; Socioeconomic
health differentials; Gender; Violence; Poverty; Health Economics; Health Legislation; Ethnicity; Ethics;
Information Technology - Virtual libraries; Research & Science issues.  [DD/ KMC Area]

“Materials provided in this electronic list are provided "as is". Unless expressly stated otherwise, the findings
and interpretations included in the Materials are those of the authors and not necessarily of The Pan American
Health Organization PAHO/WHO or its country members”.
------------------------------------------------------------------------------------
PAHO/WHO Website
Equity List - Archives - Join/remove: http://listserv.paho.org/Archives/equidad.html
Twitter http://twitter.com/eqpaho

IMPORTANT: This transmission is for use by the intended
recipient and it may contain privileged, proprietary or
confidential information. If you are not the intended
recipient or a person responsible for delivering this
transmission to the intended recipient, you may not
disclose, copy or distribute this transmission or take
any action in reliance on it. If you received this transmission
in error, please dispose of and delete this transmission. 

Thank you.